Administration of a selective retinoic acid receptor-γ agonist improves neuromuscular strength in a rodent model of volumetric muscle loss
Abstract
Volumetric muscle loss is a uniquely challenging pathology that results in irrecoverable functional deficits. Furthermore, a breakthrough drug or bioactive factor has yet to be established that adequately improves repair of these severe skeletal muscle injuries. This study sought to assess the ability of an orally administered selective retinoic acid receptor-γ agonist, palovarotene, to improve recovery of neuromuscular strength in a rat model of volumetric muscle loss.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 12, 2021
- Source ID
- 10.1186/s40634-021-00378-3
Entities
People
- Joseph C Wenke
- Masahiro Iwamoto
- Michael Whitely
- Patrick B. Collins
Organizations
- Congressionally Directed Medical Research Programs